S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
Log in
NASDAQ:GLYC

GlycoMimetics Stock Forecast, Price & News

$3.88
+0.13 (+3.47 %)
(As of 12/2/2020 04:30 PM ET)
Add
Compare
Today's Range
$3.67
Now: $3.88
$3.90
50-Day Range
$2.69
MA: $3.36
$4.03
52-Week Range
$1.82
Now: $3.88
$6.29
Volume959,758 shs
Average Volume461,751 shs
Market Capitalization$185.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist, which has completed Phase III clinical trial for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
GlycoMimetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.91 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201
Employees57

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.89 per share

Profitability

Net Income$-57,890,000.00

Miscellaneous

Market Cap$185.58 million
Next Earnings Date2/26/2021 (Estimated)
OptionableOptionable
$3.88
+0.13 (+3.47 %)
(As of 12/2/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

How has GlycoMimetics' stock been impacted by COVID-19?

GlycoMimetics' stock was trading at $2.94 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GLYC shares have increased by 32.0% and is now trading at $3.88.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of GlycoMimetics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for GlycoMimetics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than GlycoMimetics?

Wall Street analysts have given GlycoMimetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GlycoMimetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is GlycoMimetics' next earnings date?

GlycoMimetics is scheduled to release its next quarterly earnings announcement on Friday, February 26th 2021.
View our earnings forecast for GlycoMimetics
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) posted its earnings results on Friday, November, 6th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.04.
View GlycoMimetics' earnings history
.

What price target have analysts set for GLYC?

2 Wall Street analysts have issued 1 year price objectives for GlycoMimetics' stock. Their forecasts range from $15.00 to $15.00. On average, they anticipate GlycoMimetics' share price to reach $15.00 in the next year. This suggests a possible upside of 286.6% from the stock's current price.
View analysts' price targets for GlycoMimetics
.

Who are some of GlycoMimetics' key competitors?

What other stocks do shareholders of GlycoMimetics own?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the following people:
  • Ms. Rachel K. King, Pres, CEO & Director (Age 61, Pay $844.67k)
  • Dr. John L. Magnani, Sr. VP of Research & Chief Scientific Officer (Age 67, Pay $559.45k)
  • Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 52, Pay $604.72k)
  • Mr. Brian M. Hahn, Sr. VP & CFO (Age 46)
  • Ms. Stephanie R. Irish, VP of Accounting (Age 49)
  • Mr. Henry Flanner, VP of Technical Operations
  • Mr. Christian Dinneen-Long, VP, Corp. Counsel & Corp. Sec.
  • Mr. Armand Girard, Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. (Age 51)

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.15%), Camber Capital Management LP (5.23%), State Street Corp (1.41%), Acadian Asset Management LLC (0.90%), Morgan Stanley (0.64%) and ClariVest Asset Management LLC (0.28%). Company insiders that own GlycoMimetics stock include Bvf Partners L P/Il and Daniel M Junius.
View institutional ownership trends for GlycoMimetics
.

Which institutional investors are selling GlycoMimetics stock?

GLYC stock was sold by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Morgan Stanley, Arrowstreet Capital Limited Partnership, BlackRock Inc., JPMorgan Chase & Co., Squarepoint Ops LLC, and ClariVest Asset Management LLC.
View insider buying and selling activity for GlycoMimetics
.

Which institutional investors are buying GlycoMimetics stock?

GLYC stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Dupont Capital Management Corp, The Manufacturers Life Insurance Company , Connor Clark & Lunn Investment Management Ltd., State Street Corp, JBF Capital Inc., and BNP Paribas Arbitrage SA. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il, and Daniel M Junius.
View insider buying and selling activity for GlycoMimetics
.

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $3.88.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $185.58 million. The biotechnology company earns $-57,890,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. GlycoMimetics employs 57 workers across the globe.

What is GlycoMimetics' official website?

The official website for GlycoMimetics is www.glycomimetics.com.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.